Boehringer Ingelheim is in the midst of closing down its troubled Ben Venue generic sterile injectables facility in Ohio after deciding it was not worth pouring more money into its rehabilitation. But given that there is growth in generic and contract injectable manufacturing, the German company hopes someone might want to take it off its hands.
A day removed from elating investors with a $500 million cost-cutting plan, Forest Laboratories is reportedly fielding buyout interest from pharma giant AstraZeneca, discussing a deal that could soar past $15 billion.
Volcano has approved a $200 million stock repurchase plan, a sign the company is listening to an activist investor that wants it to boost its share value and find itself a buyer.
Just weeks after selling its blood-transfusion business and announcing a new strategy focusing on pharmaceutical development, Novartis is reportedly opening the books on its animal-health business to potential buyers. Bayer may be the top suiter.
HeartWare has bought out CircuLite for as much as $350 million, acquiring a cardiac assist device for less-severe patients and broadening its offerings in the heart failure world.
A few days after the feds left Seattle-based Theraclone Sciences high and dry of funds for its midstage study of an antiflu antibody, PharmAthene is now spreading the word that it is backing out of its planned merger with the biotech.
There is growth in manufacturing sterile injectable drugs and a trend toward using prefilled syringes. India's Gland Pharma does both, and investment group KKR finds that an enticing proposition. KKR India has taken a minority stake in the drugmaker, investing $200 million, buying out the entire stake held by Evolvence India Life Sciences Fund.
As CROs around the world weigh the benefits of developing their own therapies, South Korea's SillaJen has signed a deal worth up to $150 million to acquire former client Jennerex and inherit the company's Phase III-ready cancer vaccine.
Teva may not have actually planted a "for sale" sign on its front yard, but now that CEO Jeremy Levin has left the scene of many accidents some top analysts are offering to advertise it as a takeover candidate.
A few months after Jennerex and its partner Transgene reported that their oncolytic cancer vaccine Pexa-Vec flunked a Phase IIb endpoint on overall survival in liver cancer, the private South Korean CRO SillaJen has stepped in to buy the company in a deal worth up to $150 million at the high end.